- Home
- DYAI vs GDTC Comparison
DYAI vs GDTC Comparison
Compare DYAI & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- GDTC
- Stock Information
- Founded
- DYAI 1979
- GDTC 2018
- Country
- DYAI United States
- GDTC Singapore
- Employees
- DYAI N/A
- GDTC N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- DYAI Health Care
- GDTC Health Care
- Exchange
- DYAI Nasdaq
- GDTC Nasdaq
- Market Cap
- DYAI 28.3M
- GDTC 21.5M
- IPO Year
- DYAI 2004
- GDTC 2023
- Fundamental
- Price
- DYAI $1.13
- GDTC $1.89
- Analyst Decision
- DYAI Strong Buy
- GDTC Buy
- Analyst Count
- DYAI 1
- GDTC 1
- Target Price
- DYAI $6.00
- GDTC $5.00
- AVG Volume (30 Days)
- DYAI 203.9K
- GDTC 18.1K
- Earning Date
- DYAI 08-12-2025
- GDTC 01-01-0001
- Dividend Yield
- DYAI N/A
- GDTC N/A
- EPS Growth
- DYAI N/A
- GDTC N/A
- EPS
- DYAI N/A
- GDTC N/A
- Revenue
- DYAI $3,554,344.00
- GDTC $368,838.00
- Revenue This Year
- DYAI $22.56
- GDTC $5.37
- Revenue Next Year
- DYAI $30.95
- GDTC N/A
- P/E Ratio
- DYAI N/A
- GDTC N/A
- Revenue Growth
- DYAI 57.59
- GDTC N/A
- 52 Week Low
- DYAI $0.91
- GDTC $1.20
- 52 Week High
- DYAI $2.20
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- DYAI 62.78
- GDTC 37.08
- Support Level
- DYAI $1.08
- GDTC $1.85
- Resistance Level
- DYAI $1.20
- GDTC $1.95
- Average True Range (ATR)
- DYAI 0.08
- GDTC 0.10
- MACD
- DYAI 0.02
- GDTC -0.02
- Stochastic Oscillator
- DYAI 50.00
- GDTC 28.00
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.